MARKET

FBIO

FBIO

Fortress Biotech
NASDAQ

Real-time Quotes | Nasdaq Last Sale

4.040
+0.180
+4.66%
Closed 19:56 09/25 EDT
OPEN
3.834
PREV CLOSE
3.860
HIGH
4.115
LOW
3.812
VOLUME
1.14M
TURNOVER
--
52 WEEK HIGH
4.780
52 WEEK LOW
1.040
MARKET CAP
355.55M
P/E (TTM)
-4.6272
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Could The Fortress Biotech, Inc. (NASDAQ:FBIO) Ownership Structure Tell Us Something Useful?
If you want to know who really controls Fortress Biotech, Inc. (NASDAQ:FBIO), then you'll have to look at the makeup...
Simply Wall St. · 09/18 14:03
The Daily Biotech Pulse: Roche's COVID Combo Therapy Reduces Need For Ventilation, ESMO Presentations
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 17)
Benzinga · 09/18 11:30
Checkpoint Therapeutics Announces $20.0 Million Bought Deal Offering
NEW YORK, Sept. 17, 2020 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint” or the “Company”) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that it has entered into an underwriting agreement with H.C. Wainwright & Co., LLC under which the underwriter
GlobeNewswire · 09/17 21:27
The Daily Biotech Pulse: Moderna Inks 2 R&D Deals, BioNTech To Buy Manufacturing Facility, Dyne Therapeutics IPO
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 16)
Benzinga · 09/17 11:59
Checkpoint Therapeutics Announces Positive Interim Results from Registration-Enabling Trial of Cosibelimab in Metastatic Cutaneous Squamous Cell Carcinoma
51.4% objective response rate and 13.5% complete response rate in half the planned pivotal cohort Interim results presented at ESMO Virtual Congress 2020 On track to report full top-line results in
Benzinga · 09/17 10:33
Fortress Biotech Announces Initiation Of Phase 3 Study Of CAEL-101 In AL Amyloidosis
Fortress Biotech Announces Initiation of Phase 3 Studies of CAEL-101 in AL Amyloidosis - Caelum Biosciences, a company founded by Fortress, is collaborating with Alexion Pharmaceuticals on the studies   - Phase 2
Benzinga · 09/14 12:08
Fortress Biotech Announces Initiation of Phase 3 Studies of CAEL-101 in AL Amyloidosis
\- Caelum Biosciences, a company founded by Fortress, is collaborating with Alexion Pharmaceuticals on the studies \- Phase 2 study met primary objective, supporting initiation of two parallel Phase 3 studies that will enroll ~370 AL amyloidosis patients\- Positive long-term Phase 1a/1b
GlobeNewswire · 09/14 12:00
The Week Ahead In Biotech: Decision Day For Bausch Health, IPO Flow Resumes, Oncology Conference
Biotech stocks continued to remain under pressure in the week ended Sept. 11, swayed by the volatility that was evident in the broader market.
Benzinga · 09/13 13:49
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of FBIO. Analyze the recent business situations of Fortress Biotech through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 5 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average FBIO stock price target is 9.80 with a high estimate of 19.00 and a low estimate of 5.00.
EPS
Institutional Holdings
Institutions: 98
Institutional Holdings: 23.91M
% Owned: 27.16%
Shares Outstanding: 88.01M
TypeInstitutionsShares
Increased
21
9.16M
New
38
506.58K
Decreased
5
42.51K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
+0.88%
Pharmaceuticals & Medical Research
+1.58%
Key Executives
Chairman/President/Chief Executive Officer/Executive Director
Lindsay Rosenwald
Vice Chairman/Director
Eric Rowinsky
Chief Financial Officer/Treasurer/Secretary
Robyn Hunter
Corporate Executive/Executive Director
Michael Weiss
Senior Vice President
George Avgerinos
Independent Director
Jimmie Harvey
Independent Director
Malcolm Hoenlein
Independent Director
Dov Klein
Independent Director
J. Jay Lobell
Independent Director
Kevin Lorenz
  • Dividends
  • Splits
  • Insider Activity
No Data
  • All
  • Financials
  • Insiders
More
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About FBIO
Fortress Biotech, Inc.(Fortress) is a biopharmaceutical company that acquires, develops and commercializes novel pharmaceutical and biotechnology products. Fortress develops and commercializes products both within Fortress and through certain of its subsidiary companies. Fortress has 11 operating subsidiaries that include: 4 commercial stage programs, 25 development stage programs, targeting 6 therapeutic areas: Immuno-oncology, Hematology, Gene Therapy, Pain Management, Rare Diseases and Dermatology. In addition to its internal development programs, Fortress leverages its biopharmaceutical business expertise and drug development capabilities and provides funding and management services to help the Fortress Companies. Fortress subsidiaries include Aevitas Therapeutics, Avenue Therapeutics, Caelum Biosciences, Cellvation, Inc., Checkpoint Therapeutics, Cyprium Therapeutics, Helocyte, Inc., Journey Medical Corporation, Mustang Bio and Tamid Bio, Inc.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Fortress Biotech Inc stock information, including NASDAQ:FBIO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, FBIO stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading FBIO stock methods without spending real money on the virtual paper trading platform.